Summary: Recent studies have suggested that under cer tain conditions, inhalation of stable xenon can cause an increase in CBF or intracranial pressure (ICP). We re viewed the ICP changes that occurred during 48 stable xenon/CT CBF studies in 23 comatose head-injured pa tients to determine if the concentration (32%) and dura tion of inhalation (4.S min) of stable xenon we used caused an increase in ICP. In the group as a whole, there was no significant difference between the mean ICP at the start of xenon inhalation and the mean ICP immediately Several reports have suggested that the inhalation of stable xenon causes an increase in CBF (Gur et aI., 1985b; Junck et aI., 1985; Obrist et aI., 1985; Hartmann et aI., 1987) , and at least one study has found significant increases in the intracranial pres sure (ICP) of head-injured patients during Xel computed tomography (CT) CBF studies (Har rington et aI., 1986) . We consider CBF information obtained with Xe/CT studies to be important in guiding our management of head-injured patients, but are obviously concerned about potential delete rious effects of stable xenon on ICP. Therefore, we reviewed the Xe/CT CBF studies obtained over the past year to determine if the concentration of stable xenon and the duration of inhalation used in our program causes an increase in ICP.
CLINICAL MATERIALS AND METHODS
From July 1989 through February 1990, we obtained 48 Xe/CT CBF studies in 23 patients aged 14-73 years (mean of 28 years). The studies were done at times when these patients needed a plain head CT scan: immediately after
after completion of the studies. An increase in ICP also was not found in subgroups with low, normal, or high global CBF, or groups with or without intracranial hyper tension. Changes in ICP that occurred during individual studies usually were related to corresponding changes in the arterial pco2 (p < 0.0001, Pearson's correlation test). Our data suggest that 32% stable xenon administered for 4.S min does not cause a significant increase in ICP during xenon/CT CBF studies. Key Words: Xenon-Cerebral blood flow-Head injury-Intracranial pressure. assessment in the emergency room, 12 to 24 h after ad mission, and 3-10 days after injury. All studies were ob tained within 10 days after the injury, 13 within 24 h. Eight patients who had surgical intracranial mass lesions had their first CBF study 6--8 h after surgery. All patients were comatose on admission, and IS had Glasgow coma scores �6.
Xenon/CT CBF studies were obtained during a 4.S-min period of xenon inhalation using a GE-9800 CT scanner equipped for xenon CBF determinations. Technical de tails of these studies have been described elsewhere (Gur et aI., 1982) . All patients were intubated and ventilated using a volume-cycled ventilator. We used a mixture of 32% stable xenon/68% oxygen and measured peak end tidal xenon concentrations of 28-32% during the studies. Arterial oxygen saturation, heart rate, blood pressure, end-tidal pco2, end-tidal xenon, and ICP were monitored continuously. We obtained radial artery blood gas sam ples immediately before and after the studies. Table 1 lists the mean values for these variables.
Intracranial pressure (lCP) was monitored in all of these patients using an intraventricular catheter fluid coupled to a transducer. Intracranial hypertension (lCP "" 20 mm Hg) was present during the 24 h prior to study in 27 patients. To reduce elevated ICP, neuromuscular pa ralysis with vecuronium bromide was used prior to 40 of the studies, and 2S-S0 g of mannitol were given before IS studies. In no case was either of these medications given sooner than 1 h prior to the CBF study. Thirty to 40 min before initiation of the study, 34 patients required ven· tricular drainage of cerebrospinal fluid, and 2 studies were obtained in patients who were being treated with moderate hyperventilation (pco2 < 30 mm Hg). Other than in those two patients, we routinely kept arterial pco2 values at 35 ± 2 mm Hg. While administering stable xe non, we attempted to maintain a constant end-tidal pe02• Because of pulmonary trauma in many of these patients, end-tidal pe02 did not always accurately represent radial arterial pe02, however, and increases or decreases in ra dial arterial pe02 of up to 17 torr occurred during some of the studies.
Except where otherwise indicated, data were analyzed using the Student's two-tailed t test. Table 2 presents mean ICP, mean arterial pres sure (MAP), and radial arterial peo2 values obtained immediately before and immediately after the stud ies, as well as mean ICP and MAP values measured 2.5 min after beginning the study. Differences in ICP before, during, and after xenon inhalation were not statistically significant; the mean values re mained essentially the same. MAP decreased slightly during the studies, but this difference was not significant. We attempted to identify subgroups of patients who might be at risk for xenon-induced increases in ICP by stratifying studies into groups with low, medium, and high global CBF, and groups with low and high ICP (Table 3 ). There were no significant changes in ICP during the CBF studies in any of these subgroups.
RESULTS
Those decreases or increases in ICP that oc curred during individual studies usually were asso ciated with corresponding changes in the peo2 (p < 0.0001, Pearson's correlation test). In all but two studies, when ICP increased more than 2 mm Hg during the study, it was associated with an increase Values are means ± SO in mm Hg.
There were no statistically significant differences in ICP from the beginning to the end of xenon inhalation in any of these groups.
in the peo2 of 1-5 mm Hg. In the two exceptions, ICP was very unstable, and frequent ventricular drainage as well as frequent doses of mannitol were required to lower ICP during the 3 days before the CBF study. As one might expect, the effects of peo2 changes on ICP were much more pronounced in patients with intracranial hypertension (Fig. 1) .
Other than the transient increases in ICP, which were >2 mm Hg during 10 of the 48 studies but usually could be attributed to increases in peo2, sta ble xenon inhalation had no apparent deleterious effects in these patients.
DISCUSSION
Xenon/CT CBF studies are a relatively conve nient way of directly measuring regional CBF fol lowing severe head injuries, and the abnormal CBF often seen in these patients has important implica tions for the management of intracranial hyperten sion (Darby et aI., 1988) . The measurement of CBF in the first few hours after severe head injury can help to define the incidence and severity of isch emia, considered by some to be an important cause of secondary brain injury following trauma (Miller, 1985; Graham et aI., 1978) . Such early CBF infor mation also can guide the appropriate use of hyper ventilation in the management of intracranial hyper tension (Marion et aI., 1990) . Stable Xe/CT CBF studies can be obtained with the initial CT of the head and can provide information about CBF to deep brain structures that is not available with most other CBF studies.
However, because intracranial hypertension is an important cause of secondary brain injury (Marshall and Marshall, 1987) , efforts in the diagnosis and treatment of head-injured patients must be aimed at reducing high ICP, and studies that might exacer bate high ICP must be avoided. Several investiga tors have suggested that the inhalation of stable xe- non can cause an increase in CBF, which may lead to increased ICP. In rats, Junek found a 75-96% focal increase in regional CBF associated with the inhalation of 40% stable xenon for 2 min (Junek et aI., 1985) . Using the intravenous xenon-133 CBF technique, Obrist found a 28-3 1% increase in blood flows of healthy awake adult men associated with the inhalation of 30-35% stable xenon for 6 min (Obrist et aI., 1985) . Although our study was not designed to assess possible effects of xenon on CBF, Gur and colleagues compared flow values cal culated from radio labeled microsphere studies in baboons with CBF values obtained using stable Xel CT CBF techniques similar to ours (32% stable xe non administered for 4.5 min) (Gur et aI., 1985a) . They found no more than a 15% difference in CBF values obtained from the two methods. An increase in CBF does not necessarily cause an increase in ICP, however, because ICP is much more directly related to cerebral blood volume than it is to CBF (Muizelaar et aI., 1989) . For example, mannitol usually causes a decrease in ICP but an increase in CBF (Bruce et aI., 1973) , perhaps by decreasing the mean transit time of cerebral perfu sion, which would result in a decrease in cerebral blood volume (Johnston and Harper, 1973) .
There have been two previous reports of the ef fects of stable xenon on ICP in head-injured pa tients. In 1986, Harrington and co-workers studied 27 adult patients using 35% stable xenon adminis tered over 7 min and found a 16-132% increase in ICP (Harrington et aI., 1986) . However, they did not report the pco2 and blood pressure values dur ing the studies, and the CBF values of 79-110 ml 100 g-I/min -I were much higher than values re ported by most other investigators using both stable and radiolabeled xenon CBF techniques in adult head-injured patients (Obrist et aI., 1984; Mendelow et aI., 1985; Jaggi et aI., 1990; Marion et aI., 1990) . In a subsequent report, Darby and colleagues re viewed the changes in ICP in 34 Xe/CT CBF studies done on 17 patients with severe head injuries (Darby et aI., 1989) . During those studies, 32% sta ble xenon was administered over 4.5 min, and the pco2 was 24-28 torr and MAP was 97-103 torr. There was no significant increase in mean ICP val ues following the administration of stable xenon, and the maximum increase in individual studies was 5-6 mm Hg.
Based on these results and on previous studies that used the same Xe/CT CBF technique, we con clude that stable xenon should be considered safe for use in monitoring CBF in patients with severe head injuries (Latchaw et aI., 1987; Darby et aI., 1989) . Previously reported increases in ICP follow ing xenon administration, which were documented in only one study, may have been due to higher concentrations of xenon used in that study, the longer inhalation time, or changes in pco2 during the study.
